immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the diagnosis of diseases by preparing specific antibodies against synthetic fragments or the whole peptide or its derivatives and fragments and measuring the blood concentration of HF-COLL-18/514cf by immunoassays.

41. A diagnostic agent containing the peptide according to claim 22, its pharmacologically active fragments, or an antibody obtainable by immunizing an animal with said peptide and/or its pharmacologically active fragments and/or by using hybridoma technology for the test systems for checking the levels of this substance in tissues, plasma, urine and cerebrospinal liquor.

42. Fragments of the peptide according to claim 22 having pharmacological activity in humans.

REMARKS

Claims 24-42, added hereby, correspond to cancelled claims 3-21, made dependent on new claims 22 and 23 and revised to address §112, second paragraph, issues of record, and reconsideration of the rejection under 35 U.S.C. 112, second paragraph, is requested, accordingly.

Claims 1-10 and 20 were rejected under 35 U.S.C. 112, first paragraph. According to the statement of rejection, the specification does not reasonably provide enablement for the invention encompassing a "natural and pharmacologically active derivative of HF-COLL-18/514cf or any fragment of either HF-COLL-18/514cf or a derivative thereof."

The enablement rejection is directed against any natural pharmacologically active derivatives and any fragments of the peptide. To accelerate prosecution, therefore, Applicants limit the claims to the peptide of SEQ ID NO: 1 and some derivatives, thereof, by adding new claims 22 and 23.

The claims are now limited to the peptide of SEQ ID NO: 1 and specified derivatives. Applicants submit the rejection is, thus overcome.

Amidated, acetylated, phosphorylated and glycosylated derivatives of peptides are known to a person skilled in the art. Reference is made to the following publications in support, thereof.

1. Schultz, M., and H. Knz, 1995, chemical and enzymatic synthesis of glycopeptides. Exs. 73:201-28.

2. Sanderson, S.D. and F. Perini, 1995. The synthesis and compositional analysis of phosphopeptides. Mol Biotechnol. 4:139-49.

3. Hammer, R.P., F. Albericio, L. Gera, and G. Barany, 1990. Practical approach to solid-phase synthesis of C-terminal peptide amides under mild conditions based on a photolysable anchoring linkage. Int J Pept Protein Res. 36:31-45.

4. Han, Y., S.L. Bontems, P. Hegyes, M.C. Munson, C.A. Minor, S.A: KATES, f. Albericio, and G. Barany, 1996. Preparation and applications of Xanthenylamide (XAL) Handles for Solid-Phase Synthesis of C-Therminal Peptide Amides under Particularly Mild Conditions (1-3). J Org Chem. 61:6326-6339.

5. Glocker, M.O., C. Borchers, W. Fiedler, D. Suckau, and M. Przybylski, 1994: Molecular characterization of surface topology in protein tertiary structures by

amino-acylation and mass spectrometric peptide mapping. Bioconjug Chem. 5:583-90.

Furthermore, enzymatic methods are known, for example enzymatic phosphorylation.

Reconsideration is requested with respect to objections to the specification and the claims, in view of the instant Amendment.

Concerning the reference DE3633797, cited in Applicant's Information Disclosure Statement, as indicated on the International Search Report filed with the IDS, relevance of the reference is discussed in the present specification. Accordingly, the Examiner must consider the reference, and so indicate on Form PTO 1449. MPEP 609 III A(3).

Favorable action is requested.

Respectfully submitted,

By: _____
William E. Player
Reg. No.: 31,409

JACOBSON HOLMAN PLLC
The Jenifer Building
400 Seventh Street, N.W.
Washington, D.C. 20004
(202) 638-6666
Atty. Dkt. No. P63132US0
Date: **January 9, 2002**
WEP/rdt
R:\HOME\rthomas\2002\January\P63132US0-Amdt